Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Polivy | Polatuzumab Vedotin | Diffuse large B-cell lymphoma (DLBCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | ||
| Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Poteligeo | mogamulizumab | mycosis fungoides (MF), Sézary syndrome (SS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
| Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete | ||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
| Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
| Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Withdrawn | |||
| Prevymis | letermovir | Cytomegalovirus infection, prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete | ||
| Prezcobix | Darunavir/cobicistat | HIV Infection | List with criteria/condition | Complete | ||
| Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
| Prezista | Darunavir | HIV (treatment naive) | List with clinical criteria and/or conditions | Complete | ||
| Prezista | Darunavir | HIV infection (Pediatric) | List with clinical criteria and/or conditions | Complete | ||
| Pristiq | Desvenlafaxine succinate | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
| Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
| Procysbi | cysteamine bitartrate | Nephropathic cystinosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Proleukin | Aldesleukin (IL-2) | In-transit Melanoma | Reimburse | Complete | ||
| Prolia | Denosumab | Osteoporosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Prolia | Denosumab | Osteoporosis, postmenopausal women | List with clinical criteria and/or conditions | Complete | ||
| Prolia | Denosumab (Drug Plan Submission) | Osteoporosis, men | List with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024